Kornimate/medical-research-clean huggingface dataset:
microneedling plus the universal peel for acne scarring

Conditions: Acne Scarring

Summary: acne is a prevalent disorder mostly witnessed in adolescents, but can be seen in adults. early treatment is imperative to reduce acne scarring which can appear with atrophic lesions, and depending on the skin type, significant erythema (redness) or post-inflammatory hyperpigmentation. a multi-modality approach to treatment is necessary when dealing with the aforementioned types of lesions. pharmacologic management is essential, but safe procedural therapies are also necessary specifically with darker skinned individuals. percutaneous collagen induction therapy (pcit) is a non-invasive treatment achieved by using a micro-needling device, which is safe and effective in causing "micro-wounds" into the dermis thereby initiating wound healing followed by collagen production. this is an ideal treatment for acne scarring, re-texturizing of the skin, and hyperpigmentation for all skin types . currently there are very few studies evaluating the safety and efficacy of microneedling and chemical peels in skin types iii-vi. the aim of this study is to evaluate the effects of the combination of microneedling and chemical peel for the treatment of acne scars in skin types iii-vi.


Eligibility criteria:
inclusion criteria: * subject \> 18 and \< 60 years of age. * subject has skin type iii, iv, v, or vi as defined by the fitzpatrick classification scale. * subject has acne scarring as defined by the goodman and baron grading system. exclusion criteria: * subject currently has moderate to severe acne on the face. * subject has an active infection. * subject is pregnant or lactating. * subject has a history of a bleeding disorder. * subject is taking an anti-coagulant. * subject has a history of keloidal tendency. * subject has received ablative or non-ablative laser treatments in the previous 6 months. * subject has taken accutane within the previous 3 months.
changes in brain structure related to systemic chemotherapy treatment: a prospective study in individuals diagnosed with non-small cell lung cancer utilizing high-resolution structural magnetic resonance imaging

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to learn about the effects of cancer treatment on the brain. some cancer patients report changes in their memory or thinking after treatment. these changes could be a result of changes in brain structure, such as a change in size or thickness of different parts of the brain. the investigators will look to see if these changes in brain structure happen through the results of magnetic resonance imaging (mri). the investigators will do this by looking at the brain structure of lung cancer patients who have surgery and chemotherapy versus those who have surgery only.


Eligibility criteria:
inclusion criteria: * patients between the ages of 18 and 80 years old * as per self report and/or medical record female patients are either postmenopausal or not able to become pregnant * patients with biopsy proven or suspected non-small cell lung cancer planned to undergo induction chemotherapy and surgery, or with biopsy proven or suspected non-small cell lung cancer planned to undergo immediate surgical resection * no clinical/neurological symptoms suggestive of brain metastases by attending's judgment as documented in the medical record and/or correspondence with the research team * in the judgement of the consenting professional, patient is able to understand english, through verbal and written communication * patient is able to undergo mri scanning (verified with pre-mri safety screening form (appendix a) used in mskcc mri centers) completed at screening and again prior to having the mri. exclusion criteria: * patients with history of significant neurological diagnoses including stroke, tumor, dementia, epilepsy, or multiple sclerosis as indicated by medical records and/or self report * history of head injury with evidence of brain injury or loss of consciousness for \> 60 minutes as per emr or self-report * no prior treatment with chemotherapy * participant has dentures, body jewelry or wig that they are unable to remove as per self-report * patient reports that he/she cannot undergo mri scanning without significant distress or discomfort * significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the study (i.e., schizophrenia).

Keywords: quality of life lung cancer mri surgery induction chemotherapy 11-145
t-lymphocytes cd8+/hla-dr+ and acute rejection after lung transplantation

Conditions: Transplant Failure

Summary: the objectives of the study is to identify associations between acute rejection and the increase of t (cd4/cd8) and b circulating lymphocytes expressing specific markers of activation and differentiation (hla-dr, cd25, cd38, cd45ro, ccr7). 110 adults over 18 years, on national waiting list for a first lung transplantation in the centers of marseille and strasbourg, whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets t lymphocytes will be included. peripheral venous blood sampling just prior to pulmonary transplantation, at day 15 and one month post-transplant will be realized for lymphocyte phenotyping by flow cytometry (cd45, cd3, cd4, cd8, cd19, hla-dr, cd25, cd38, cd45ro, ccr7). acute rejection will be evaluated at 1 month and 1 year post-transplant by trans-bronchial biopsies. the two main perspectives are to 1) find a specific, non-invasive, blood-based diagnostic marker of acute post-lung transplant rejection with diagnostic performance equivalent to trans-bronchial biopsy 2) demonstrate a specific blood marker, non-invasive, predictive of acute rejection in order to adapt immunosuppressive therapy early and reduce the occurrence of this risk.

the objectives of the study is to identify associations between acute rejection and the increase of t (cd4/cd8) and b circulating lymphocytes expressing specific markers of activation and differentiation (hla-dr, cd25, cd38, cd45ro, ccr7). 110 adults over 18 years, on national waiting list for a first lung transplantation in the centers of marseille and strasbourg (france), whatever the lung disease, and who will be transplanted and benefit immunosuppressive induction therapy that specifically targets t lymphocytes will be included. peripheral venous blood sampling just prior to pulmonary transplantation, at day 15 and one month post-transplant will be realized for lymphocyte phenotyping by flow cytometry (cd45, cd3, cd4, cd8, cd19, hla-dr, cd25, cd38, cd45ro, ccr7). acute rejection will be evaluated at 1 month and 1 year post-transplant by trans-bronchial biopsies. the two main perspectives are to 1) find a specific, non-invasive, blood-based diagnostic marker of acute post-lung transplant rejection with diagnostic performance equivalent to trans-bronchial biopsy 2) demonstrate a specific blood marker, non-invasive, predictive of acute rejection in order to adapt immunosuppressive therapy early and reduce the occurrence of this risk.

Eligibility criteria:
inclusion criteria: * \>18 years old * french national waiting list of lung transplantation * transplanted in marseille or strasbourg (france) exclusion criteria: * \<18 years old * refused to participate * redo lung transplantation * other organ transplanted
a study of p38 inhibitor (4) in patients with active rheumatoid arthritis (ra) on stable methotrexate therapy

Conditions: Rheumatoid Arthritis

Summary: this 6 arm study will evaluate the efficacy and safety of different doses of p38 inhibitor (4) in patients with ra currently having an inadequate clinical response to methotrexate. patients will be randomized to receive p38 inhibitor (4) (50,150 or 300 qd po,and 25 or 75 bid po) or placebo, and will remain on the stable dose of methotrexate. the anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * active rheumatoid arthritis; * current inadequate clinical response to methotrexate. exclusion criteria: * receiving any other disease-modifying anti-rheumatic drug, with the exception of hydroxychloroquine or chloroquine.
effectiveness of trauma management therapy and prolonged exposure therapy

Conditions: PTSD

Summary: the purpose of this requirement is to identify an effective exposure psychotherapy paradigm for the treatment of post-traumatic stress disorder (ptsd) in active duty service members and veterans by comparing different exposure psychotherapy modalities. the long-term goal of exposure psychotherapy is to improve the mental health of u.s. service members and veterans with military-related ptsd. recovery from ptsd will reduce the economic burden not only for those persons experiencing ptsd, but also for the health care system and society as a whole (galovski \& lyons, 2004).

this study will provide an evaluation of performance and suitability of the compressed versions of exposure psychotherapy to support the capability gap for the treatment of active duty service members and veterans with ptsd by comparing different exposure psychotherapy modalities. the overall objective of this study is to determine if compressed psychotherapy can be used as an effective alternative treatment for ptsd and to compare the impact of tmt and pe on social, familial, and occupational impairment. the primary objectives will be to compare 1) 3 week tmt with 12 week pe and 2) 3 week tmt with 2 week pe for the effectiveness of reducing ptsd symptoms in a gated approach or some other method to control for multiplicity. outcomes will be determined based upon self-report, clinician ratings, as well as other aspects of psychopathology, and social/emotional functioning. the addition of the tmt group component will be assessed in particular to determine its impact on social, familial, and occupational impairment. blood samples should be collected from participants at baseline and at the end of the treatment period in order to identify ptsd biomarkers, e.g. predictors of response, biological subtypes of ptsd, and therapeutic markers. collection, storage, and transfer of the blood samples to dod should be performed according to standardized protocols provided by the dod. one or more site visits may occur in order to assess adherence to standardized protocols.

Eligibility criteria:
inclusion criteria: * active duty military personnel with a diagnoses of ptsd * traumatic event must have occurred during military service * military sexual trauma limited to attempted or completed sexual assault. exclusion criteria: * acute cardiac difficulties * severe comorbid substance use disorders. * diagnosis of schizophrenia or other psychotic disorders * diagnosis of antisocial personality disorder * moderate or severe traumatic brain injury (tbi) * use of benzodiazepines

Keywords: trauma management therapy exposure therapy group therapy ptsd military
observational study of tildrakizumab in patients with moderate to severe plaque psoriasis in routine clinical practice

Conditions: Plaque Psoriasis

Summary: the observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.


Eligibility criteria:
inclusion criteria: * written informed consent form. * age \>= 18years. * moderate to severe chronic plaque psoriasis diagnosis. * participants who have participated in tildrakizumab (ilumetri®) clinical trials (cohort 1) or participants who, according to the physician's therapeutic decision, should start the treatment with tildrakizumab (ilumetri®) (cohort 2). exclusion criteria: * unable to comply with the requirements of the study or who in the opinion of the study physician should not participate in the study. * participants meeting any of the exclusion criteria specified in the summary of product characteristics (smpc) of ilumetri®.

Keywords: ilumetri® tildrakizumab moderate to severe plaque psoriasis
"minimed 640g system" user evaluation with the question of reducing the rate of hypoglycemia

Conditions: Type 1 Diabetes

Summary: the minimed®640g system (mm640g) consists of a combination of insulin and glucose sensor for continuous glucose monitoring (cgm). here, the glucose sensor transmits not only the continuous glucose data on the display of insulin pump but, in the case of hypoglycemia also interrupt their insulin delivery of pump. in the currently available system paradigm®veo, the interruption takes place at a settled threshold level. in difference in the new system mm640g the shutdown algorithm can already be proactive and help avoid hypoglycemia completely. the so called plgm algorithm (predictive low glucose management) should be tested in the user evaluation. the main objective is to answer the question of reducing the rate of hypoglycemia by application of the new plgm algorithm. included are a total of 24 patients, aged 1-21 years, in three pediatric diabetes centers.

in the first phase of two weeks, the sensor-augmented pump therapy (sap) is carried out without these interruption plgm algorithm. in a second phase for 6 weeks, the plgm function is set. both phases are compared in terms of the rate of hypoglycemia, the time spent and the area under the curve (auc) glucose range (values \<70 mg / dl (3.9 mmol / l)).

Eligibility criteria:
inclusion criteria: * type 1 diabetes, diagnosed since 12 month at least * continuous subcutaneous insulin infusion (csii) since 3 month at least * stable outcome since 3 month at least * willingness of patients/ parents to wear a glucose sensor for 2 month * willingness of patients/ parents to use the minimed®640g system * willingness of patients/ parents to complete a diary * willingness of patients/ parents to comply the requirements of the study protocol exclusion criteria: * longer absence of the patients (not able to attend the study visits) * subject with allergy of sensor or specific sensor components * communication problems * significant history of eating disorder, anorexia, bulimia * pregnancy * significant history of drug abuse or/ and alcoholism * patient do not want to attend the trial * missing informed consent
fat supplementation on dumping syndrome associated symptoms

Conditions: Dumping Syndrome

Summary: the purpose of the study is the investigation of the effect of fat supplement on gastric emptying rate and the appearance of symptoms of dumping syndrome in patients who have undergone gastrointestinal- duodenal surgery. patients who have undergone bariatric surgery have been examined for the presence of the dumping syndrome, with glucose measurements, the sigstad's questionnaire and questionnaire of arts. patients diagnosed positive, reiterated the examination process in a second meeting consuming an extra fat supplement. the data obtained on the different appointments were compared between the two groups in a cross over design.


Eligibility criteria:
inclusion criteria: * patients with dumping syndrome exclusion criteria: * patients with diabetes mellitus type 1 and 2, patients with impaired balance of fluids and electrolytes, patients on diuretics pills or corticosteroids or hypoglycemic tablets and insulin.

Keywords: dumping syndrome fat supplement post bariatric surgery
outcomes after transoral incisionless fundoplication (tif) following successful endoscopic ablation for barrett's esophagus

Conditions: Barrett Esophagus; Transoral Incisionless Fundoplication

Summary: barrett's esophagus (be) is a precancerous lesion characterized by the replacement of the normal stratified squamous epithelium of the distal esophagus by intestinal metaplasia (im). non-dysplastic be may progress to low-grade dysplasia (lgd), to high-grade dysplasia (hgd) and esophageal adenocarcinoma (eac). endoscopic ablation is safe and effective for complete eradication of be. however, recurrence is common. cumulative incidence rate of be recurrence is up to 30% in the third year. thus, achieving complete eradication of im, patients should undergo surveillance indefinitely with serial endoscopy to assess for recurrence of be. in addition, be patients have been committed to life-long proton pump inhibitor (ppi) therapy, but increasing concerns about adverse effects has led to alternative therapies. studies have showed that laparoscopic nissen fundoplication may decrease recurrence of be after endoscopic ablation. transoral incisionless fundoplication (tif) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative nissen fundoplication. the role of tif in patients with be whom underwent successful endoscopic ablation has not been fully investigated.


Eligibility criteria:
inclusion criteria: * age 18 - 75 years * known prior diagnosis of histologically-confirmed be with or without dysplasia (as defined by the presence of specialized columnar epithelium anywhere in the tubular esophagus with \>= 1 cm of circumferential involvement or non-circumferential involvement of specialized columnar epithelium) \[prague class \>1\] and history of initial complete eradication-im following endoscopic ablation for barrett's esophagus. * documentation of complete ablation of be by endoscopy and histology after radiofrequency or cryotherapy ablation on two endoscopic examinations at least 3 months apart, within most recent endoscopy performed within 6 months. pathologic diagnosis determined by the expert pathologist at each site. * on ppi therapy, who opt for an intervention over lifelong drug dependence. * hiatal hernia ≤ 2 cm or hill grade \< 2 \[unless patients undergoing combined tif and hiatal hernia repair\] * abnormal esophageal acid exposure \[percent esophageal acid exposure time \> 6% defined by bravo ph monitoring (48 - 96 hours study) * able to provide informed consent exclusion criteria: * age \ 75 years * inability to provide informed consent
effect of tadalafil once a day in men with erectile dysfunction

Conditions: Erectile Dysfunction

Summary: the primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ed) who are naïve to pde5 (phosphodiesterase type 5) inhibitors. patients may be dose reduced to 2.5mg based on tolerability.


Eligibility criteria:
inclusion criteria: * you are male and aged at least 18 years. * have a history of erectile dysfunction (ed)(defined as the consistent inability to achieve and/or maintain an erection sufficient to permit satisfactory sexual intercourse) of at least 3 months duration. * agree not to use any other treatment for ed, including herbal and over-the-counter (otc) medications, during the study * you agree to make at least four sexual intercourse attempts with the female sexual study partner during the 4-week run-in period without medication * your entry laboratory test results and medical tests meet study requirements * you agree to use the study drug only as instructed by your study doctor and staff and to return any unused study drug and containers at the end of the study or as otherwise instructed by the study doctor. * if currently using cholesterol lowering medications (for example: statins) or medications to lower blood pressure (example: angiotensin-converting enzyme (ace) inhibitors or calcium channel blocker medications), you need to be on a stable dose and you and your study doctor do not expect any dose change during the study. exclusion criteria: * you have received previous or current treatment with tadalafil or any other pde5 inhibitor. * currently receives treatment with doxazosin, nitrates, cancer chemotherapy, or anti-androgens (except finasteride e.g. propecia™ or proscar®, or dutasteride e.g. avodart®). * you have had significant heart disease as determined by your doctor in charge of this study or a member of the doctor's staff. * have a history of significant central nervous system injuries (including stroke or spinal cord injury) within the last 6 months. * have a history of loss of vision in one eye because of nonarteritic anterior ischemic optic neuropathy (naion), regardless of whether this episode was in connection or not with previous pde5 inhibitor exposure.

Keywords: erectile dysfunction
effect of intranasal mupirocin on rate of staphylococcus aureus surgical site infection following cesarean sections

Conditions: Surgical Wound Infection; Cesarean Section; Staphylococcus Aureus

Summary: the investigators believe that irradication of nose colonization of staphyloccocus aureus will reduce the incidence of surgical site infections after cesarean section.


Eligibility criteria:
inclusion criteria: * women assigned to undergo cesarean section exclusion criteria: * all others
the effect of combination of red and white bahman retrieved of iranian traditional medicine on semen parameters in idiopathic oligospermic men

Conditions: Infertility, Male

Summary: this study is a prospective double blind randomized controlled trial to investigate the effect of red and white bahman on semen parameters, sexual hormones and dna defragmentation in idiopathic oligospermic men .include patients will take the medicine and placebo in different two case and control groups for 3 month and semen parameters and other variants at the start and end of study.

this is a randomized, double blind; placebo-controlled clinical trial has been started from july 2016 and will continue to july 2016 in royan institute. the eligible patients who fulfilled the study criteria will be included in the trial. study protocol and assays all the patients will have a complete history evaluation and physical examination by the attending urologist who is blinded to the study and enter the study according to inclusion criteria.. semen analysis and hormonal laboratory tests \[testosterone, luteinizing hormone (lh) follicle stimulating hormone(fsh)\] will done in same lab at start of study and 3 month after. intervention time is 3 month for each patient. semen analysis wil be done according to who laboratory manual for the examination and processing of human semen 5th edition and hormonal tests (lh,fsh,testosterone) with elisa method (with score of international unit). dna defragmentation will evaluate with sperm chromatin structure assay(scsa) method. semen parameters which will evaluate is the number of normal and abnormal shape sperms, velocity of sperms, volume and viscosity of semen at start and end of the study. medicine and placebo prescribe in 500mg capsules for 3month. red and white bahman is an effective medicine in male infertility treatment in iranian traditional medicine. at the end of study main aim of the study is evaluation effect of combination of red and white bahman retrieved of iranian traditional medicine on semen parameters in idiopathic oligospermic . red bahman and white bahman ,nutrition ,placebo, smoking and testosterone,lh,fsh,concentration,number,sha-pe,of sperm before and after the study is variables of study.

Eligibility criteria:
inclusion criteria: 1. all idiopathic oligospermic patient in range of 20 to 45 years old 2. sperm count under 15 million /ml 3;no history of taking chemical or herbal medicine effective on sperm genesis in last 3 month( like hormonal drug ,antidepressant ,anti hypertension,cimetidine, cyproteron, sulphasalazine, flutamide, spironolactone, estrogen,opium 4:no history of varicocele and obstructive disease 5:;no leukocytospermia exclusion criteria: taking chemical or herbal medicine effective on spermatogenesis (hormonal and sperm reducing and increasing agent); 2. ; increasing bmi \> 30 3. leukocytospermia 4. varicocele

Keywords: semen parameters male infertility oligospermia traditional medicine